Alzheimer's disease is the world's most common dementing illness. Deposition of amyloid-b peptide drives cerebral neuroinflammation by activating microglia 1, 2 . Indeed, amyloid-b activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1b maturation and subsequent inflammatory events 3 . However, it remains unknown whether NLRP3 activation contributes to Alzheimer's disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer's disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3 2/2 or Casp1 2/2 mice carrying mutations associated with familial Alzheimer's disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer's disease, and demonstrated reduced brain caspase-1 and interleukin-1b activation as well as enhanced amyloid-b clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-b in the APP/PS1 model of Alzheimer's disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer's disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
The chronic deposition of amyloid-b stimulates the persistent activation of microglial cells in Alzheimer's disease 1 . Increased interleukin (IL)-1b amounts have been implicated in the response to amyloid-b deposition 2 . IL-1b is produced as a biologically inactive pro-form and requires caspase-1 for activation and secretion. Caspase-1 activity is controlled by inflammasomes, sensors of microbial components and sterile danger signals. The NLRP3 inflammasome has been implicated in several chronic inflammatory diseases as it can sense inflammatory crystals and aggregated proteins, including amyloid-b 3, 4 . Because of the possibility that the neuroinflammatory component of Alzheimer's disease involves inflammasome activation, we assessed the cleavage of caspase-1 in brains from patients with Alzheimer's disease, early-onset Alzheimer's disease and mild cognitive impairment. We observed substantially increased amounts of cleaved caspase-1 in hippocampal or cortical lysates from those patients' brains compared with controls ( Fig. 1a and Supplementary Fig. 1 ), consistent with chronic inflammasome activation 4 . This increase of caspase-1 processing was mirrored in aged APP/PS1 transgenic mice (Fig. 1b ). APP/PS1 mice express a human/ mouse chimaeric amyloid precursor protein and human presenilin-1, each carrying mutations associated with familial Alzheimer's disease 5 , leading to the chronic deposition of amyloid-b, neuroinflammation and cognitive impairment.
Nlrp3 2/2 mice were crossed into APP/PS1 mice to obtain APP/PS1/ Nlrp3 2/2 mice to assess the contribution of the NLRP3 inflammasome to the pathogenesis of Alzheimer's disease. In APP/PS1/Nlrp3 2/2 mice, caspase-1 cleavage was absent. Total brain IL-1b amounts were similar to those in wild-type (WT) animals ( Fig. 1b, c) . Immunohistochemistry for the inflammasome component ASC detected microglial 'speck' formation in activated (Iba1 1 ) microglia cells from APP/PS1 mice, consistent with inflammasome activation (Fig. 1d ). We assessed spatial memory formation in age-matched 16-month-old WT, Nlrp3 2/2 , Casp1 2/2 , APP/PS1, APP/PS1/Nlrp3 2/2 and APP/PS1/ Casp1 2/2 mice using the Morris water-maze test including probe trial testing. As expected, aged APP/PS1 mice showed severe deficits in spatial memory formation. However, APP/PS1/Nlrp3 2/2 and APP/ PS1/Casp1 2/2 mice were largely protected from spatial memory impairment (Fig. 1e, f and Supplementary Figs 2-9 ). These results were supported by object recognition memory testing (Supplementary Fig. 10 ). Again, NLRP3-or caspase-1-deficient APP/PS1 mice were protected from memory deficits ( Supplementary Fig. 10 ). To assess the effect of NLRP3 or caspase-1 gene deficiency on neuronal function in murine Alzheimer's disease, we determined hippocampal synaptic plasticity, which is considered to represent the basis of newly formed declarative memories and is often analysed by measuring longterm potentiation (LTP) 6, 7 . NLRP3 or caspase-1 deficiency completely prevented LTP suppression in hippocampal slices from APP/PS1 mice ( Fig. 1g and Supplementary Fig. 11 ). Baseline synaptic transmission and short-term plasticity (measured as paired-pulse facilitation) were unaltered ( Supplementary Fig. 12 ). An analysis of spine morphology showed a small but statistically significant reduction of spine density in the pyramidal neurons of APP/PS1 mice, which was prevented by NLRP3 or caspase-1 deficiency ( Supplementary Fig. 13 ). The small degree of spine density reduction suggested that LTP suppression in APP/PS1 mice was primarily mediated by functional rather than structural changes. Body weight and blood glucose amounts were similar between groups of mice ( Supplementary Fig. 14) . Behavioural analysis in the open field arena verified increased locomotion and slowed habituation in APP/PS1 mice, similar to previous reports 8 . APP/PS1/ Nlrp3 2/2 mice, however, had a reduced hyperdynamic phenotype and normalized habituation ( Fig. 1h and Supplementary Fig. 15 ), suggesting that NLRP3 deficiency improved neurobehavioural disturbances such as Alzheimer's-disease-like psychomotor disinhibition. These results support a fundamental role for NLRP3/caspase-1-mediated inflammation in behavioural and cognitive dysfunction in Alzheimer's disease.
Alzheimer's-disease-associated inflammation interferes with APP metabolism and with mechanisms of amyloid-b aggregation and clearance at several levels 9, 10 . Thioflavin S staining showed a marked decrease in hippocampal and cortical amyloid-b deposition in the APP/PS1/Nlrp3 2/2 mice ( Fig. 2a, b and Supplementary Fig. 16 ). Additionally, APP/PS1/Nlrp3 2/2 mice showed a 70% reduction in brain concentrations of highly aggregated, formic-acid-extractable forms of amyloid-b ( Fig. 2c ). This reduction was most probably not due to changes of APP expression and processing, as formation of carboxy (C)-terminal fragments or amounts of b-secretase-1 (BACE1) messenger RNA (mRNA) and protein ( Fig. 2 and Supplementary Fig. 17 ) were unaffected in NLRP3 knockout mice. This conclusion was further strengthened by the analysis of 4-month-old APP/PS1 mice; neither NLRP3 nor caspase-1 deficiency influenced amyloid-b amounts (Supplementary Fig. 18 ). However, aggregated forms of amyloid-b were markedly reduced in the APP/PS1/Nlrp3 2/2 mice, as shown by the further quantification of amyloid-b species by enzyme-linked immunosorbent assay (ELISA). These studies showed a strong reduction of amyloid-b 1240 and amyloid-b 1242 in the APP/PS1/Nlrp3 2/2 mice after sequential extraction by radio-immunoprecipitation assay (RIPA) and sodium dodecyl sulphate (SDS) buffer, allowing the analysis of soluble and insoluble amyloid-b ( Fig. 2d ). At 16 months of age, amyloid-b 1238 was only detectable in SDS extracts. Again, analysis of the APP/PS1/ Nlrp3 2/2 mice showed reduced amounts compared with APP/PS1 mice ( Supplementary Fig. 19 ). Analysis of cerebral amyloid-b amounts of APP/PS1 and APP/PS1/Casp1 2/2 mice showed that caspase-1 deficiency resulted in similar changes in amyloid-b, suggesting that NLRP3 acts through caspase-1 to exert the observed effects ( Supplementary  Figs 20 and 21) .
As both amyloid-b and IL-1b have been implicated in the suppression of LTP [11] [12] [13] , their reduction may jointly contribute to the protection of LTP, improved spatial memory and normalized behaviour in the NLRP3-deficient APP/PS1 mice.
Microglia are found in increased numbers in close proximity to amyloid-b plaques in Alzheimer's disease. Microglia assembly in the vicinity of plaques is interpreted as an attempt to clear the pathological deposits of amyloid-b through phagocytosis and degradation. The functional impact of phagocytosis is highlighted by studies showing that restricting microglial accumulation and phagocytosis increases amyloid-b deposition 14, 15 . As Alzheimer's disease progresses, microglial cells adopt a chronically activated phenotype. Cytokines, including IL-1b, were found to impair microglial clearance functions 16, 17 . Likewise, suppression of inflammatory cytokine production resets microglial phagocytosis in APP/PS1 mice 17 . We analysed the impact of NLRP3 or caspase-1 deficiency on the phagocytic capacity of microglia in vivo because immunohistochemistry showed microglial ASC and NLRP3 expression ( Fig. 1d and Supplementary Figs 22 and 23a ). In addition, we observed that inflammasome activation occurred in an age-and amyloid-b deposition-related fashion ( Supplementary Figs 23b and  24 ). We administered a fluorescent derivative of Congo red known as methoxy-XO4, which crosses the blood-brain barrier and has nanomolar binding affinity for amyloid-b. We injected methoxy-XO4 into adult APP/PS1, APP/PS1/Nlrp3 2/2 and APP/PS1/Casp1 2/2 mice. Three hours after injection, methoxy-XO4 fluorescence in brain homogenates did not differ between groups ( Supplementary Fig. 25 ). At this LETTER RESEARCH point, mice were euthanized and microglial cells were isolated and analysed for methoxy-XO4 fluorescence by flow cytometry. An increase of nearly twofold in amyloid-b phagocytosis was found in APP/PS1/ Nlrp3 2/2 or APP/PS1/Casp1 2/2 compared with APP/PS1 mice ( Fig. 3a, b ), suggesting that NLRP3/caspase-1 inflammasome activation reduces amyloid-b phagocytosis. Microglia were isolated from brains by cytospin. Co-immunostaining again showed microglial ASC speck formation ( Fig. 3c ). Methoxy-XO4 labelled amyloid-b was detected within CD11b 1 microglia and co-localized to Lamp2positive, amyloid-b-containing lysosomes ( Fig. 3d and Supplementary  Fig. 26 ). Notably, increased uptake of methoxy-XO4 labelled amyloid-b was associated with enhanced CD36 expression ( Supplementary Fig. 27 ).
Although the methoxy-XO4 assay cannot functionally distinguish between increased phagocytosis and impaired degradation, we performed further microscopy. This showed that NLRP3 deficiency substantially altered the characteristics of amyloid-b plaque deposition (Fig. 3e, f and Supplementary Fig. 28 ). First, the total volume of the amyloid-b plaque was reduced in APP/PS1/Nlrp3 2/2 mice compared with APP/PS1 mice ( Fig. 3g ). Second, APP/PS1/Nlrp3 2/2 mice showed more reduction in the outer parts of the amyloid-b plaque than in the core. Furthermore, microglial cells surrounding amyloid-b plaques in APP/PS1 mice phagocytosed amyloid-b to a lesser extent ( Fig. 3e, g and Supplementary Fig. 29 ).
Together with the documented suppression of microglial phagocytosis by proinflammatory cytokines, these data argue for an increase in phagocytosis in APP/PS1/Nlrp3 2/2 mice. These results may be surprising, because they seemingly contradict a report that experimental local overproduction of IL-1b reduced amyloid-b deposition 18 . However, there are two explanations for these apparently opposite results. First, the NLRP3/ caspase-1-axis may use substrates other than IL-1b to constrain microglial amyloid-b phagocytosis. Second, it is likely that the experimental approach that was used by Shaftel et al. disrupted the blood-brain barrier, allowing amyloid-b removal by peripherally derived myeloid cells 19 . Similar effects on amyloid-b plaque metabolism have been observed after whole-body irradiation, which also leads to disruption of the blood-brain barrier 1 . Shielding the APP/PS1 brain from radiation restricted the infiltration of peripheral cells to a level that did not significantly contribute to the clearance of parenchymal amyloid-b 20 .
In addition to phagocytosis, microglia also contribute to amyloid-b clearance through proteolytic enzymes, including insulin-degrading enzyme (IDE) and neprilysin (NEP) 21 . Cerebral homogenates from APP/PS1/Nlrp3 2/2 or APP/PS1/Casp1 2/2 mice demonstrated an increase of IDE whereas NEP amounts remained unchanged ( Fig. 4a and Supplementary Fig. 30 ). Microglial cells purified from 
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16-month-old mice were one source of increased IDE transcription (Fig. 4b) . Previous work established that a twofold increase of IDE expression is sufficient to reduce amyloid-b deposition strongly 22 . It is likely that the IDE increase enhances the degradation of amyloid-b and the overall amyloid-b reduction in inflammasome-deficient mice. These data suggest that NLRP3 activation negatively affects the microglial clearance function in Alzheimer's disease. Notably, recent evidence suggests that impaired clearance may be the driving force behind sporadic Alzheimer's disease 23 , which constitutes the overwhelming majority of cases of human Alzheimer's disease. Prolonged exposure to amyloid-b leads to persistent activation of microglial cells in Alzheimer's disease. On the basis of gene expression profiles, activated microglial cells may be divided into several different populations. The M1 and M2 subtypes represent the extremes of the range. Markers of alternatively activated microglia of the M2 subtype 24 , including 'found in inflammatory zone 1' (FIZZ1) ( Supplementary  Fig. 31 ), arginase-1 and interleukin-4, showed increased expression in APP/PS1/Nlrp3 2/2 and APP/PS1/Casp1 2/2 mice ( Fig. 4c-e ). In contrast, cerebral nitric oxide synthase 2 (NOS2), a hallmark of the classically activated M1 proinflammatory phenotype, was reduced in inflammasome-deficient APP/PS1 mice (Fig. 4f, g) . Thus, NLRP3-or caspase-1-deficiency results in a skewing of activated microglial cells towards an M2-like activated state. This M2 phenotype is also characterized by increased amyloid-b clearance and enhanced tissue remodelling. In Alzheimer's disease, the upregulation of NOS2 results in tyrosine nitration of several proteins, including amyloid-b, thereby accelerating its aggregation and seeding of new plaques 25 . In agreement with this, APP/PS1/Nlrp3 2/2 mice had less nitrated amyloid-b and a reduced average plaque size as well as fewer nitrated plaque cores ( Fig. 4h-j) . Because NO and nitrated amyloid-b act as strong LTP suppressors 25, 26 , a reduction of NOS2 and nitrated amyloid-b (Fig. 4g, j) should contribute to the protection of synaptic plasticity, memory and behaviour.
These data are consistent with the hypothesis that amyloid-b-induced activation of the NLRP3 inflammasome enhances Alzheimer's disease progression by mediating a harmful chronic inflammatory tissue response. Inflammatory mediators that result from NLRP3 inflammasome activation are probably involved in mediating synaptic dysfunction, cognitive impairment and the restriction of beneficial microglial clearance functions. This key role of the NLRP3 inflammasome in amyloidb-mediated inflammatory responses suggests that a therapeutic that blocks the activity of the NLRP3 inflammasome, or inflammasomederived cytokines, might effectively interfere with the progression of Alzheimer's disease. 
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METHODS SUMMARY
Caspase-1 activation of human and mouse brain tissue was analysed by western blot of cleaved caspase-1. IL-1b was quantified by ELISA. Microglial ASC speck formation was detected by immunohistochemistry. All mice were on C57/Bl6 background, including WT, Nlrp3 2/2 (ref. 27) , APP/PS1 (ref. 5), APP/PS1/ Nlrp3 2/2 , Casp1 2/2 (ref. 28 ) and APP/PS1/Casp1 2/2 , and were analysed for cognitive function using the Morris water-maze test, the object recognition test and open field behavioural testing. Synaptic plasticity was determined by measuring LTP in acutely isolated hippocampal slices. Spine density was assessed by analysing mid-apical dendritic sections of pyramidal CA1 neurons. Cerebral amyloid-b load was determined by thioflavin S immunohistochemistry of serial sections. Sequential extraction of homogenized brains by radio-immunoprecipitation assay, sodium dodecyl sulphate buffer and formic acid was used to determine amounts of amyloid-b. Amyloid-b nitration was determined by ELISA and immunohistochemistry using specific antibodies against 3NTyr 10 -amyloid-b 25 .
Western blot detection was used to analyse the protein amounts of APP, carboxylterminal fragments, amyloid-b, BACE1, IDE and NOS2. Inflammasome activation was confirmed by detection of ASC speck formation in microglia isolated from adult mouse. Microglial amyloid-b phagocytosis was determined after peripheral injection of methoxy-XO4, isolation of microglia and subsequent FACS analysis. Confirmatory immunocytochemistry was performed using antibody IC16 and the lysosomal marker LAMP2. Plaque morphology and microglial amyloid-b uptake were analysed by coimmunostaining with Iba-1, methoxy-XO4 and IC16. mRNA amounts of IDE, NEP, M1 and M2 markers were determined either from sorted microglia or from brain tissue by quantitative PCR.
Full Methods and any associated references are available in the online version of the paper.
METHODS
Animals and ages. APP/PS1 transgenic animals 5 were obtained from The Jackson Laboratory (number 005864) on the C57BL/6 background. NLRP3-deficient animals 27 (Millennium Pharmaceuticals) were backbred onto C57BL/6 mice genotype to more than 99% C57BL/6, which was confirmed by microsatellite analysis. Caspase-1-deficient mice were generated by BASF 28 ; these mice were subsequently obtained by M. Starnbach, who provided the mice for this study after 10 generations of backbreeding onto the C57BL/6 background. All mice were housed under standard conditions at 22 uC and a 12 h light:dark cycle with free access to food and water. Animal care and handling was performed according to the Declaration of Helsinki and approved by the local ethical committees. The following animal groups were analysed: WT, Nlrp3 2/2 , APP/PS1, APP/PS1/Nlrp3 2/2 , Casp1 2/2 , APP/PS1/Casp1 Mice were trained to find the platform, orienting by three extra maze cues placed asymmetrically as spatial references. They were placed into the water in a quasi-random fashion to prevent strategy learning. Mice were allowed to search for the platform for 40 s; if the mice did not reach the platform in the allotted time, they were placed onto it manually. Mice were allowed to stay on the platform for 15 s before the initiation of the next trial. After completion of four trials, mice were dried and placed back into their home cages. Mice trained four trials per day for eight consecutive days. For spatial probe trials, which were conducted 24 h after the last training session (day 9), the platform was removed and mice were allowed to swim for 30 s. The drop position was at the border between the third and fourth quadrant, with the mouse facing the wall at start. Data are given as the percentage of time spent in quadrant Q1, representing the quadrant where the platform had been located, and compared with the averaged time the animals spent in the remaining quadrants. In the afternoon of the same day, a visual cued testing was performed with the platform being flagged and new positions for the start and goal during each trial. All mouse movements were recorded by a computerized tracking system that calculated distances moved and latencies required for reaching the platform (Noldus, Ethovision 3.1). For open field exploration, mice were placed in the centre of the dimly lit (20-30 lx) chamber of the open field arena. Animal movements were tracked by an automatic monitoring system (Noldus Ethovision 3.1) for 5 min. The area was virtually divided into a centre (square with 40 cm edge lengths), a corridor (7.5 cm along the walls) and four corner squares (10 cm edge lengths), which partly overlapped with the corridor area. The time spent in each area, horizontal and vertical activity, frequency of urination and defaecation were monitored. The experiment was repeated on three consecutive days. The novel object recognition test was performed according to a previously established protocol with minor changes 29 . Briefly, the test procedure consisted of three sessions: habituation, training and retention. Each mouse was individually habituated to the open field arena. Habituation was allowed for 10 min. One day later, during the training session, two identical objects (object A) were placed into the two opposing corners of the centre area 30 cm apart from each other, and mice were allowed to explore the area and the objects for 10 min. The total time spent exploring both identical objects was recorded to examine place or object preference. Exactly 60 min or 1 day later, during the retention sessions, mice were placed back into the same arena in which one familiar (object A) and one novel object (object B) replacing the second object A were placed. Mice were then allowed to explore freely for 5 min and the time spent exploring each object was recorded. Exploration of the object was considered when the head of the animal was at least facing the object from a minimum distance of 1-2 cm or closer, but recording was cut as soon as mice turned their heads away from the previously investigated object. Time spent exploring the objects during trials was determined and is shown as discrimination ratio (novel object interaction/total object interaction). The arena and all objects were thoroughly cleaned with 70% ethanol solution after each trial. Electrophysiology. For slice preparation, acute hippocampal transversal slices were prepared from 7-to 9-month-old WT, Nlrp3 2/2 , APP/PS1 or combined APP/PS1/ Nlrp3 2/2 and APP/PS1/Casp1 2/2 mice according to standard procedures. In brief,
